Skip to main content

HNSCC

11
Pipeline Programs
13
Companies
10
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
5
0
6
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
360%
Small Molecule
120%
RNA Therapeutic
120%
+ 10 programs with unclassified modality

Competitive Landscape

13 companies ranked by most advanced pipeline stage

Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
2 programs
2
Pembrolizumab, CetuximabPhase 2Monoclonal Antibody
eftilagimod alphaPhase 2
MSD
MSDIreland - Ballydine
2 programs
2
Pembrolizumab, CetuximabPhase 2Monoclonal Antibody1 trial
eftilagimod alphaPhase 2
Active Trials
NCT03082534Completed78Est. Sep 2025
Flamingo Therapeutics
Flamingo TherapeuticsBelgium - Leuven
1 program
1
DanvatirsenPhase 2RNA Therapeutic1 trial
Active Trials
NCT05814666Terminated69Est. Aug 2025
Immutep
ImmutepGermany - Berlin
1 program
1
eftilagimod alphaPhase 21 trial
Active Trials
NCT04811027Completed171Est. Nov 2025
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
1
Alpha Lipoic AcidPhase 11 trial
Active Trials
NCT04042935Completed5Est. Sep 2021
Phio Pharmaceuticals
Phio PharmaceuticalsPA - King of Prussia
1 program
1
DP CD8 TILPhase 1
AgonOx
AgonOxOR - Portland
1 program
1
DP CD8 TILPhase 11 trial
Active Trials
NCT05902520Active Not Recruiting18Est. Dec 2026
Presage Biosciences
1 program
1
MotolimodPhase 11 trial
Active Trials
NCT04272333Terminated1Est. Mar 2022
Keymed Biosciences
Keymed BiosciencesChina - Chengdu
1 program
1
Stapokibart and FinotonlimabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT07040072Not Yet Recruiting10Est. Jun 2028
Grit Biotechnology
Grit BiotechnologyChina - Shanghai
1 program
GT201 in combination with PD-1 inhibitorsN/A1 trial
Active Trials
NCT06190275Recruiting32Est. Apr 2027
Martin Pharmaceuticals
1 program
Special Care Patterns for Elderly HNSCC Patients Undergoing RadiotherapyN/A1 trial
Active Trials
NCT05337631Recruiting1,500Est. Dec 2026
Providence Therapeutics
1 program
DP CD8 TILPHASE_1
Kura Oncology
Kura OncologySAN DIEGO, CA
1 program
TipifarnibPHASE_1_2Small Molecule1 trial
Active Trials
NCT04997902Completed45Est. Jul 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Flamingo TherapeuticsDanvatirsen
Immutepeftilagimod alpha
MSDPembrolizumab, Cetuximab
Kura OncologyTipifarnib
Keymed BiosciencesStapokibart and Finotonlimab
AgonOxDP CD8 TIL
Presage BiosciencesMotolimod
Colorado TherapeuticsAlpha Lipoic Acid
Grit BiotechnologyGT201 in combination with PD-1 inhibitors
Martin PharmaceuticalsSpecial Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy

Clinical Trials (10)

Total enrollment: 1,929 patients across 10 trials

NCT05814666Flamingo TherapeuticsDanvatirsen

Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC

Start: May 2023Est. completion: Aug 202569 patients
Phase 2Terminated
NCT04811027Immutepeftilagimod alpha

Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC

Start: Aug 2021Est. completion: Nov 2025171 patients
Phase 2Completed
NCT03082534MSDPembrolizumab, Cetuximab

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Start: Mar 2017Est. completion: Sep 202578 patients
Phase 2Completed
NCT04997902Kura OncologyTipifarnib

Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Start: Dec 2021Est. completion: Jul 202545 patients
Phase 1/2Completed
NCT07040072Keymed BiosciencesStapokibart and Finotonlimab

Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCC

Start: Jun 2025Est. completion: Jun 202810 patients
Phase 1Not Yet Recruiting
NCT05902520AgonOxDP CD8 TIL

Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors

Start: Jun 2023Est. completion: Dec 202618 patients
Phase 1Active Not Recruiting
NCT04272333Presage BiosciencesMotolimod

Intratumoral Microdosing of Motolimod in HNSCC

Start: Oct 2021Est. completion: Mar 20221 patients
Phase 1Terminated
NCT04042935Colorado TherapeuticsAlpha Lipoic Acid

Alpha Lipoic Acid to Decrease Pain and Side Effects in Concurrent Treatment of HNSCC

Start: Feb 2020Est. completion: Sep 20215 patients
Phase 1Completed
NCT06190275Grit BiotechnologyGT201 in combination with PD-1 inhibitors

Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors

Start: May 2024Est. completion: Apr 202732 patients
N/ARecruiting
NCT05337631Martin PharmaceuticalsSpecial Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy

Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy

Start: Jun 2021Est. completion: Dec 20261,500 patients
N/ARecruiting

Related Jobs

Facilities & Lab Coordinator

Kura OncologyKura Oncology
San Diego, CA
1w ago
$21 - $30/hr

Senior Director, Medical & Regulatory Writing

Kura OncologyKura Oncology
Remote
2w ago
$265K - $306K/yr

Senior Director, Pharmacovigilance (Safety Science & Surveillance)

Kura OncologyKura Oncology
Remote
2w ago
$274K - $330K/yr

Oncology Account Manager - NYC

Kura OncologyKura Oncology
New York City
3w ago
$210K - $230K/yr

Senior Manager, Field Training on Product & Disease - 1 year maternity cover

Ascendis PharmaAscendis Pharma
Hellerup, Capital Region of Denmark, Denmark (Hybrid)
1mo ago

Director, Clinical Trial Management

Kura OncologyKura Oncology
Boston, Massachusetts
1mo ago
$228K - $252K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 1,929 patients
13 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.